Latest news with #F.Hoffmann-LaRocheLtd
Yahoo
15-05-2025
- Business
- Yahoo
Lucentis (Ranibizumab) Market Research Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2019-2024, 2024-2029F, 2034F
Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Lucentis (Ranibizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to Lucentis (Ranibizumab) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market. Major players operating in the lucentis (ranibizumab) market are Roche Ltd, Novartis AG. North America was the largest region in the lucentis (ranibizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lucentis (ranibizumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the lucentis (ranibizumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, growth in the historic period can be attributed to the growing prevalence of age-related macular degeneration (AMD), approval and reimbursement by regulatory authorities, demonstrated efficacy and clinical outcomes, strong brand recognition, and physician adoption of Lucentis. The emergence of biosimilars and increased cost competition also played a significant role in driving market growth during the forecast period can be attributed to the increasing incidence of diabetic retinopathy (DR) and diabetic macular edema (DME), advancements in treatment protocols and combination therapies, and the aging population contributing to a rising prevalence of retinal diseases. Additionally, expanding market access in emerging markets, ongoing clinical research, and the potential for new indications will boost growth. Major trends in the forecast period include a shift toward longer-interval dosing and maintenance treatment, growing adoption of biosimilars and alternative treatments, the rise of personalized medicine approaches for retinal diseases, increased demand in emerging markets due to improving healthcare access, and the integration of digital health solutions in treatment monitoring. The rising prevalence of eye-related disorders is expected to drive the growth of the lucentis (ranibizumab) market. Eye-related disorders encompass various conditions that impair the proper functioning of the eyes, and their prevalence is increasing due to factors such as aging, genetic predisposition, lifestyle choices like smoking and poor diet, and environmental influences such as prolonged sun exposure and excessive digital screen use. Lucentis works by inhibiting vascular endothelial growth factor (VEGF), which is responsible for abnormal blood vessel growth and leakage in the retina, common causes of conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME). According to the National Eye Institute, 2.2 million Americans will be blind by 2030, indicating a growing need for treatments like Lucentis. Thus, the rising prevalence of eye-related disorders is driving the market for rise in healthcare spending is a key factor propelling the growth of the lucentis (ranibizumab) market. Healthcare spending, which includes financial resources allocated by individuals, governments, and insurers for healthcare services and products, is increasing due to factors like an aging population, advancements in medical technology, and the rising prevalence of chronic diseases. This growth in healthcare expenditure helps to ensure that treatments like Lucentis are accessible, enabling widespread use in treating retinal diseases such as AMD and DME. It also supports the reimbursement, coverage, and distribution of the drug, ultimately improving patient outcomes and reducing the long-term burden of vision loss. For instance, healthcare spending in the UK increased by 5.6% in 2023, reflecting a larger trend of rising healthcare investments that support the lucentis market.A key trend in the lucentis (ranibizumab) market is the development of biosimilars to offer more affordable alternatives to the branded product. Biosimilars are biologic medical products that are highly similar to an already approved reference biologic in terms of structure, efficacy, and safety, with no clinically meaningful differences. For example, in April 2024, Formycon AG and Bioeq AG launched FYB201, a biosimilar version of Lucentis, in Canada and Switzerland. Known as Ranopto and Ranivisio in these markets, respectively, the biosimilar provides a more cost-effective option for patients suffering from retinal diseases. Like Lucentis, FYB201 inhibits VEGF-A, a protein that causes abnormal blood vessel growth in the retina, leading to conditions like swelling and vision impairment. The approval and launch of such biosimilars contribute to market growth by expanding access to Topics Covered: 1. Executive Summary2. Lucentis (Ranibizumab) Market Characteristics3. Lucentis (Ranibizumab) Market Biologic Drug Characteristics3.1. Molecule Type3.2. Route of Administration (ROA)3.3. Mechanism of Action (MOA)3.4. Safety and Efficacy4. Lucentis (Ranibizumab) Market Trends and Strategies5. Lucentis (Ranibizumab) Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market6. Global Lucentis (Ranibizumab) Growth Analysis and Strategic Analysis Framework6.1. Global Lucentis (Ranibizumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)6.2. Analysis of End Use Industries6.3. Global Lucentis (Ranibizumab) Market Growth Rate Analysis6.4. Global Lucentis (Ranibizumab) Historic Market Size and Growth, 2019-2024, Value ($ Billion)6.5. Global Lucentis (Ranibizumab) Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)6.6. Global Lucentis (Ranibizumab) Total Addressable Market (TAM)7. Global Lucentis (Ranibizumab) Market Pricing Analysis & Forecasts8. Lucentis (Ranibizumab) Market Segmentation8.1. Global Lucentis (Ranibizumab) Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Single-use Prefilled Syringe Single-use Glass Vial 8.2. Global Lucentis (Ranibizumab) Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Age-related Macular Degeneration Diabetic Retinopathy Retinal Vein Occlusion Myopic Choroidal Neovascularization Uveitis 8.3. Global Lucentis (Ranibizumab) Market, Segmentation by End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Hospitals Clinics Ambulatory Surgical Centers Other End-Users 9. Global Lucentis (Ranibizumab) Market Epidemiology of Clinical Indications9.1. Drug Side Effects9.2. Incidence and Prevalence of Clinical Indications10. Lucentis (Ranibizumab) Market Regional and Country Analysis10.1. Global Lucentis (Ranibizumab) Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion10.2. Global Lucentis (Ranibizumab) Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
06-05-2025
- Health
- Yahoo
Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity
F. Hoffmann-La Roche Ltd Elecsys PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets), assesses liver fibrosis severity – a disease responsible for approximately one in every 25 deaths worldwide 1 The test delivers results in just 18 minutes on Roche's cobas analysers, providing a fast and reliable diagnostic method. The test enables earlier identification of patients with significant liver fibrosis, potentially improving outcomes through timely management and access to emerging therapies. Basel, 06 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of its Elecsys® PRO-C3 test, a new diagnostic solution designed to assess the severity of liver fibrosis in patients showing signs of metabolic dysfunction–associated steatotic liver disease (MASLD). The test, developed in partnership with Nordic Bioscience, offers clinicians a simple and efficient method of identifying patients with liver fibrosis of varying severity, enabling timely intervention and appropriate management of the disease. MASLD affects around 30% of the population,2 and is one of the most common causes of chronic liver disease in the developed world.3 Caused mainly by diabetes, obesity and other cardiometabolic risk factors,3 a rapidly growing number of people are living with MASLD, representing a significant burden for patients and health systems worldwide. However, despite being responsible for approximately one in every 25 deaths globally,1 the liver fibrosis associated with MASLD is often asymptomatic until the advanced stages and can go undetected for years. Unmanaged, it can lead to severe consequences such as cirrhosis, liver cancer, and liver failure. "The Elecsys PRO-C3 test addresses an urgent need in the diagnosis, staging and management of liver fibrosis," said Matt Sause, CEO of Roche Diagnostics. "With MASLD affecting a growing number of people worldwide and new treatments emerging, it is critical to detect fibrosis accurately and early. Our innovative solution simplifies the diagnostic process and eases the burden on healthcare services, providing a clear and rapid assessment while reducing the requirement for invasive biopsies." Until recently, no medicines were available to treat MASLD, and disease management options were focused on lifestyle interventions such as diet and exercise. New drug treatments for liver fibrosis are now emerging, giving clinicians, for the first time, a means of improving liver function and slowing disease progression. The Elecsys PRO-C3 test requires only a single assay, which delivers results in only 18 minutes on Roche's cobas® analysers. This streamlines the process compared to currently available tests and reduces costs. Used in combination with the ADAPT formula,4 which includes PRO-C3 levels, platelet count, age and diabetes status, it provides a clear assessment of the severity of fibrosis, including distinguishing between different severities such as significant fibrosis (≥F2), advanced fibrosis (≥F3), and cirrhosis (F4). This is crucial for determining the appropriate treatment pathway for patients and identifying those who are eligible for new and emerging therapies.
Yahoo
11-04-2025
- Business
- Yahoo
Nucleic Acid Amplification Testing Market Size to Hit USD 20.62 Billion by 2032, Driven by Precision Diagnostics and Infectious Disease Surveillance
According to SNS Insider, Nucleic Acid Amplification Testing Market Growth is Fueled by Technological Advancements and Expanding Clinical Applications. Austin, April 11, 2025 (GLOBE NEWSWIRE) -- According to a new report by SNS Insider, the Nucleic Acid Amplification Testing (NAAT) Market, valued at USD 7.36 billion in 2023, is projected to reach USD 20.62 billion by 2032, growing at a compound annual growth rate (CAGR) of 12.16% over the forecast period from 2024 to 2032. This significant growth is attributed to technological advancements in diagnostic techniques and an increasing emphasis on the early detection of diseases. The U.S. Nucleic Acid Amplification Testing Market, valued at USD 2.17 billion in 2023, is projected to reach USD 5.77 billion by 2032, growing at a compound annual growth rate (CAGR) of 11.48% over the forecast period from 2024 to a Sample Report of Nucleic Acid Amplification Testing Market@ Market Overview The NAAT market in the United States has grown significantly over the years due to a robust healthcare infrastructure, and an emphasis on early detection of diseases has been increased in the country. Advanced diagnostic technologies have further advanced the market because of the ever-increasing rate of infectious diseases and the urgency for accurate solutions for diagnosis. The NAAT market is experiencing strong growth because of the rising incidence of infectious diseases like influenza, hepatitis, and sexually transmitted diseases. The need for precise and speedy diagnostic techniques has caused a universal adaptation of NAAT technologies. In addition, continued technological evolution, especially in Polymerase Chain Reaction (PCR) methodologies, has improved the precision and effectiveness of these tests and made them a key factor in driving market growth. Major Players Analysis Listed in this Report are: F. Hoffmann-La Roche Ltd Becton, Dickinson and Company Danaher Corporation Abbott Laboratories Illumina, Inc. Siemens Healthineers AG bioMérieux SA Novartis AG Bio-Rad Laboratories, Inc. Seegene Inc. QIAGEN N.V. Nucleic Acid Amplification Testing Market Report Scope Report Attributes Details Market Size in 2023 US$ 7.36 billion Market Size by 2032 US$ 20.62 billion CAGR CAGR of 12.16% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Key Regional Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) Segment Analysis By Type In 2023, Polymerase Chain Reaction (PCR) tests became the most prominent segment in the NAAT market, with a significant revenue share. The reason for the dominance of PCR tests lies in their high specificity, sensitivity, and capacity to identify a wide variety of pathogens. Moreover, the ongoing advancements in PCR technology, such as the invention of real-time PCR and digital PCR, have widened its clinical diagnostic applications, further establishing its market dominance. Isothermal Nucleic Acid Amplification Technology (INAAT) tests are expected to be the most rapidly growing segment over the forecast period. Advances like loop-mediated isothermal amplification (LAMP) have made the process of amplification easier, allowing for rapid and affordable diagnostics. The fact that INAAT tests can work at constant temperatures without the requirement of advanced equipment makes them highly appropriate for point-of-care applications, leading to their growth and adoption. By Application Infectious disease testing accounted for the highest revenue share in 2023 due to the worldwide prevalence of infectious diseases and the urgent need for timely and precise diagnostics. The COVID-19 pandemic further highlighted the significance of NAAT in controlling infectious outbreaks, resulting in higher usage of these tests. Oncology testing is also expected to grow at the highest rate during the forecast period. The advent of advances in molecular diagnostics has made it easier to detect genetic mutations and biomarkers related to different types of cancers. The increasing focus on personalized medicine and the early detection of cancer is driving demand for NAAT in oncology applications. By End-Use Central and reference labs led the market for NAAT in 2023 with a large revenue share. These labs are well-equipped with modern infrastructure and experienced professionals, which enables them to conduct high-throughput testing with accuracy. The centralization of such facilities facilitates the effective processing of bulk samples, leading to market leadership. Point-of-care settings are anticipated to experience the fastest growth over the forecast period. The trend towards decentralized healthcare and the demand for quick diagnostics have prompted the invention of portable NAAT devices. These devices allow for instant decision-making and are capable of enhancing patient outcomes, especially in resource-constrained settings. Need Any Customization Research on Nucleic Acid Amplification Testing Market, Enquire Now@ Nucleic Acid Amplification Testing Market Segmentation By Type Polymerase Chain Reaction (PCR) Tests Isothermal Nucleic Acid Amplification Technology (INAAT) Tests Ligase Chain Reaction (LCR) Tests By Application Infectious Disease Testing COVID-19 Testing Mosquito-Borne Disease Testing Influenza Testing Sexually Transmitted Infections Testing Hepatitis Testing Tuberculosis Testing Others Oncology Testing Genetic & Mitochondrial Disease Testing Others By End-use Hospitals Central And Reference Laboratories Others Regional Analysis In 2023, North America dominated the NAAT market with the largest revenue share, fueled by sophisticated healthcare infrastructure, high levels of adoption of cutting-edge diagnostic technologies, and a strong emphasis on the detection of diseases in the early stages. The location of major market players and continuous research and development activities also contribute to the position of the region. The Asia-Pacific market is expected to have the highest growth over the forecast period. The growth is driven by a large and heterogeneous patient pool, growing healthcare spending, and increasing awareness of early disease diagnosis. Moreover, government efforts towards enhancing healthcare access and the development of local manufacturing units are expected to drive the adoption of NAAT in the region. Recent Developments In March 2023, BD (Becton, Dickinson, and Company) received FDA 510(k) clearance for the BD Vaginal Panel on the BD COR System, a high-throughput molecular diagnostic test for large laboratories. This test enables the direct detection of the three most common infectious causes of vaginitis, enhancing diagnostic accuracy and a Single-User PDF of Nucleic Acid Amplification Testing Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 6. Competitive Landscape 7. Nucleic Acid Amplification Testing Market by Type 8. Nucleic Acid Amplification Testing Market by Application 9. Nucleic Acid Amplification Testing Market by End-use 10. Regional Analysis 11. Company Profiles 12. Use Cases and Best Practices 13. Conclusion Access Complete Report Details of Nucleic Acid Amplification Testing Market Analysis & Outlook 2024-2032@ [For more information or need any customization research mail us at info@ About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Globe and Mail
08-04-2025
- Business
- Globe and Mail
Minimal Residual Disease Testing Market is Expected to Reach $2.3 Billion
"Asia Pacific MRD testing market is expected to be worth USD 554.1 million by 2029, growing at CAGR of 13.6% during the forecast period." The global minimal residual disease testing market, valued at US$1.27 billion in 2023, is forecasted to grow at a robust CAGR of 12.2%, reaching US$1.43 billion in 2024 and an impressive US$2.55 billion by 2029 In the near future, the Minimal Residual Disease (MRD) testing industry is poised to experience remarkable growth and transformative advancements. As precision medicine gains momentum, MRD testing will become an integral component in cancer management and treatment evaluation. Technological innovations will enhance the sensitivity and specificity of MRD detection methods, enabling earlier and more accurate detection of residual cancer cells post-treatment. Next-generation sequencing, liquid biopsy approaches, and innovative biomarker identification will revolutionize the landscape, allowing for non-invasive and real-time monitoring of MRD. Moreover, the integration of artificial intelligence and machine learning algorithms will streamline data analysis and interpretation, empowering clinicians to make data-driven decisions tailored to individual patient needs. This amalgamation of cutting-edge technologies and personalized medicine will undoubtedly revolutionize the MRD testing industry, facilitating more effective cancer therapies and ultimately improving patient outcomes. Minimal Residual Disease Testing market in terms of revenue was estimated to be worth $1.2 Billion in 2022 and is poised to reach $2.3 Billion by 2027, growing at a CAGR of 14.0% from 2022 to 2027 according to a latest report published by MarketsandMarkets™. Factors such as the rising prevalence of cancer and hematological malignancies, growing initiatives undertaken by government bodies to create awareness about cancer, and increasing collaborations are factors driving the growth of the global minimal residual disease testing market. Minimal Residual Disease Testing market major players covered in the report, such as: Labcorp Inc. (US) F. Hoffmann-La Roche Ltd. (Switzerland) Guardant Health (US) Sysmex Corporation (Japan) NeoGenomics Laboratories, Inc. (US) Adaptive Biotechnologies Corporation (US) ArcherDX, Inc. (US) Asuragen Inc. (US) Arup Laboratories Inc. (US) Bio-Rad Laboratories, Inc. (US) Cergentis B.V. (Netherlands) Molecular MD (ICON plc) (Ireland) Invivoscribe, Inc. (US) Mission Bio, Inc. (US) Natera, Inc. (US) Opko Health, Inc. (US) Quest Diagnostics (US) Genetron Health (China) and Among Others Buy Minimal Residual Disease Testing Industry Report (179 Pages PDF with Insightful Charts, Tables, and Figures): This report categorizes the minimal residual disease testing market into the following segments and subsegments: By Technology Flow Cytometry Polymerase Chain Reaction (PCR) Next-Generation Sequencing (NGS) Other Technologies By Application Hematological Malignancies Leukemia Lymphoma Solid Tumors Other Applications By End User Hospitals and Specialty Clinics Diagnostic Laboratories Academic & Research Institutes Other End Users By Region North America US Canada Europe Germany UK France Italy Spain Rest of Europe Asia Pacific China Japan India Rest of Asia Pacific Latin America Middle East & Africa The key stakeholders in the Minimal Residual Disease Testing market include: Healthcare Providers: Oncologists, hematologists, and other healthcare professionals who order MRD testing for cancer patients as part of their treatment monitoring and management. Diagnostic Laboratories: Clinical and specialized laboratories that conduct MRD testing, process samples, and provide test results to healthcare providers and patients. Pharmaceutical Companies: Companies involved in developing and producing cancer therapies and treatments, as MRD testing plays a crucial role in clinical trials and assessing treatment efficacy. Research Institutions: Academic and private research institutions that contribute to the advancement of MRD testing technologies and methodologies. Patients: Individuals diagnosed with cancer who undergo MRD testing to assess treatment response and potential disease recurrence. Regulatory Authorities: Government bodies and agencies responsible for overseeing and approving MRD testing technologies, ensuring their safety and efficacy. Insurance Providers: Health insurance companies that may cover or reimburse the cost of MRD testing for eligible patients. Technology Providers: Companies offering MRD testing platforms, equipment, and software for laboratories and healthcare facilities. Patient Advocacy Groups: Organizations representing patients with cancer, advocating for improved access to and affordability of MRD testing and related treatments. Healthcare Administrators: Hospital and clinic administrators who manage the integration of MRD testing into the broader healthcare system. As the MRD testing market continues to expand, collaboration and coordination among these stakeholders will be vital to drive innovation, improve patient outcomes, and ensure the effective implementation of MRD testing in cancer care. Frequently Asked Questions (FAQs) of Minimal Residual Disease Testing Market: What are the recent trends affecting the minimal residual disease testing market?Ans. Recent trends affecting the minimal residual disease testing market are the rising incidence and prevalence of hematological malignancies and cancer, cancer awareness initiatives undertaken by global health organizations. What are the major application areas of minimal residual disease testing market?Ans. Based on application, the minimal residual disease testing market is segmented into hematological malignancies, solid tumors and other applications. Who are the key players in the minimal residual disease testing market?Ans. The key players operating in this market are Labcorp Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Guardant Health (US), Sysmex Corporation (Japan), NeoGenomics Laboratories, Inc. (US), Adaptive Biotechnologies Corporation (US), ArcherDX, Inc. (US), Asuragen Inc. (US), Arup Laboratories Inc. (US), Bio-Rad Laboratories, Inc. (US), Cergentis B.V. (Netherlands), Molecular MD (ICON plc) (Ireland), Invivoscribe, Inc. (US), Mission Bio, Inc. (US), Natera, Inc. (US), Opko Health, Inc. (US), Quest Diagnostics (US), and Genetron Health (China), among are the major end users of minimal residual disease testing products & services?Based on end user, the minimal residual disease testing market has been segmented into reference laboratories, hospitals and physician laboratories, academic & research centers, and other end users. Which region is lucrative for the minimal residual disease testing market?Ans. Like China, Japan, and India, the emerging economies in the Asia Pacific region will be the lucrative markets for minimal residual disease testing market. Get 10% Free Customization on this Report: Report Objectives: To define, describe, segment, and forecast the global minimal residual disease testing market by technology, application, end user, and region To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges) To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall minimal residual disease testing market To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies To track and analyze company developments such as product launches, agreements, partnerships, and acquisitions in the minimal residual disease testing market To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy Media Contact Company Name: MarketsandMarkets™ Research Private Ltd. Contact Person: Mr. Rohan Salgarkar Email: Send Email Phone: 18886006441 Address: 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 City: Florida State: Florida Country: United States Website:
